Reimbursement Review Reports


( Last Updated : August 11, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Truxima Rituximab Cancelled
Kivexa Abacavir/lamivudine HIV infection List in a similar manner to other drugs in class Complete
TBC abaloparatide Osteoporosis, postmenopausal women Received
Orencia Abatacept Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid List with clinical criteria and/or conditions Complete
Orencia Abatacept Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Orencia Abatacept Arthritis, rheumatoid List with clinical criteria and/or conditions Complete
Orencia Abatacept Arthritis, Rheumatoid List in a similar manner Complete
Verzenio Abemaciclib Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Active
Zytiga Abiraterone Withdrawn